Navigation Links
RIKEN Center for Genomics Medicine Chooses Genedata Expressionist for High Throughput Proteomics R&D
Date:2/16/2010

Japan’s Largest Research Organization Uses Expressionist’s Data Processing and Analysis Capabilities to Eliminate Mass Spectrometry Data Analysis Bottlenecks

Basel, Switzerland and Tokyo, Japan (PRWEB) -- Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that the Japanese research foundation RIKEN has chosen Genedata Expressionist to support biomarker development for cancer research. The renowned government foundation is using proteome analysis and Mass Spectrometry (MS) to identify biomarkers to aid in the development of serum-based diagnostic methods.

“We generate huge volumes of MS data in our proteomics facility,” explained Dr. Koji Ueda, a project leader at the Laboratory for Biomarker Development at RIKEN. “Data analysis has been a major bottleneck and Genedata Expressionist is the only solution we found that can meet our high throughput needs.”

RIKEN’s biomarker development group is using the Refiner MS and Analyst modules from the Genedata Expressionist system for high throughput LC-MS-based proteomics data processing and analysis. Refiner MS processes thousands of samples and terabytes of raw MS data and combines intuitive visualization with sophisticated algorithms for peak intensity and alignment correction, detection, quantification and matching.

“In the field of Clinical Proteomics there has been a great need to quantitatively analyze as many clinical samples as possible because of individual variations, and we had problems with the alignment of such a huge amount of MS data. However, Refiner MS solved them for us,” continued Ueda. “Now, we can confidently quantify and identify peaks, which has improved our overall biomarker development. In addition, using Analyst we can focus on sophisticated statistical analysis tasks, which allow data-mining from all perspectives and help us find the best predictive biomarkers in human sera.”

RIKEN is one of Japan’s leading research facilities and they are making great strides in discovering biomarkers for early cancer diagnosis and risk identification,” said Dr. Othmar Pfannes, CEO of Genedata. “We are honored to have Genedata Expressionist chosen as the computational solution for biomarker research at this prestigious institute, which underscores Genedata’s continuing expansion in Japan.”

About RIKEN Center for Genomic Medicine
Founded in 2000 as a part of Japan's Millennium Genome Project, the RIKEN Center for Genomic Medicine was known as the RIKEN SNP Research Center until it adopted its current name in 2008. The main aim of this center is to construct infrastructure for the realization of personalized medicine through the establishment of large-scale, high-throughput SNP genotyping technologies. Using these techniques, researchers systematically analyze SNPs in the human genome and search for disease-related genes, genes related to drug response and examine the effect of SNPs on gene function. www.src.riken.go.jp/english

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead and biomarker discovery. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher, Genedata Screener, and Genedata Expressionist make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Japan, Germany and the US. www.genedata.com.

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

###

Read the full story at http://www.prweb.com/releases/mass_spectrometry/personalized_medicine/prweb3605574.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
2. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
3. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
4. UniCare Unveils Community Resource Center in Topeka to Serve Medicaid Enrollees
5. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
6. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
7. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
8. Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project
9. Midwest Research Institute Launches Center for Biological Safety and Security (CBS2)
10. Kaiser Permanente Colorado Opens Center for Health Dissemination and Implementation Research
11. Beaumont Technology Usability Center To Offer Training For Medical Technology Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Microbial genomics ... Awards. uBiome is one of just six company finalists in the Health & ... to uBiome, companies nominated as finalists in this year’s awards include Google, SpaceX, ...
(Date:12/8/2016)... -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), ... products to treat rare diseases where there is an ... hosting an Investor Webcast Event Friday, December 16, 2016, ... defense regulators (IDRs) as a new drug class, as ... recently announced and published Phase 2 clinical data for ...
(Date:12/8/2016)... Eutilex Co. Ltd. today announced that it ... A financing. This financing round included participation from DS ... Bio Angel. This new funding brings the total capital ... since its founding in 2015. The ... commercialization of its immuno-oncology programs, expand its R&D capabilities ...
(Date:12/7/2016)... ... 07, 2016 , ... ACEA Biosciences, Inc. presented today updated ... trial for its lead drug candidate, AC0010, at the World Conference on Lung ... determine the safety, antitumor activity, and recommended phase II dosage of AC0010 in ...
Breaking Biology Technology:
(Date:11/29/2016)... , November 29, 2016 Nearly one billion matches ... Reading ... DERMALOG ... of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's ...
(Date:11/22/2016)... According to the new market research report "Biometric System Market ... Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, and Region ... to grow from USD 10.74 Billion in 2015 to reach USD 32.73 ... Continue Reading ... ...
(Date:11/19/2016)... -- Securus Technologies, a leading provider of civil and ... and monitoring, announced today that it has offered a ... independent technology judge determine who has the largest and ... calling platform, and the best customer service. ... what we do – which clearly is not the ...
Breaking Biology News(10 mins):